Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
M.D. Anderson Cancer Center
With
OBJECTIVES: Primary * Determine the increase in clinical/radiographic complete response rate in patients with previously untreated metastatic squamous cell carcinoma of the head and neck treated with induction therapy comprising cetuximab, carboplatin, and paclitaxel. * Determine the toxic effects of this regimen in these patients. Secondary * Determine the pattern of tumor recurrence in patients treated with this regimen. * Determine the quality of life of patients treated with this regimen. * Determine the duration of response, time to progression, and survival of patients treated with this regimen. * Correlate effects of this regimen with biomarkers of response and predictors of long-term outcome in these patients. OUTLINE: This is a nonrandomized, open-label study. Patients receive induction therapy comprising cetuximab IV over 1-2 hours, paclitaxel IV over 1 hour, and carboplatin IV over 1 hour on day 1. Treatment repeats weekly for up to 6 courses in the absence of disease progression or unacceptable toxicity. Beginning 2-3 weeks later, patients undergo radiotherapy or chemoradiotherapy. Patients with T0, 1, 2 disease undergo radiotherapy 5 days a week for 6 weeks. Patients with T3, 4 disease or unresectable nodal disease undergo radiotherapy 5 days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours on days 1 and 22. Some patients may undergo primary surgical resection before or instead of radiotherapy or chemoradiotherapy. Quality of life is assessed at baseline and at 6, 12, and 24 months after completion of radiotherapy or surgery. After study completion, patients are followed every 3 months for 2 years, every 4 months for 1 year, and every 6 months for 2 years. PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
